EUVIMEDOpdag EUVIMED
Crossref

Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study

Taishi Hirai iD, J Aaron Grantham, David E Kandzari, William Ballard, W Morris Brown, Keith B Allen, Ajay J Kirtane iD, Michael Argenziano, Robert W Yeh, Kamal Khabbaz, William Lombardi, John Lasala and 5 more

Catheterization and Cardiovascular Interventions · 2023

DOI: 10.1002/ccd.30834 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, 2023. Written by Taishi Hirai and 16 co-authors. Institution: Division of Cardiology, University of Missouri, Columbia, Missouri, USA. Major MEDLINE topics: Percutaneous Coronary Intervention, Heart-Assist Devices. Cited 3 times so far (Crossref); 23 references. Funded by: Boston Scientific Corporation, Abiomed.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Indications and outcomes for percutaneous ventricular assist device (pVAD) use in surgically ineligible patients undergoing percutaneous coronary intervention (PCI) remain poorly characterized.

Aims

We sought to describe the use and timing of pVAD and outcome in surgically ineligible patients.

Methods

Among 726 patients enrolled in the prospective OPTIMUM study, clinical and health status outcomes were assessed in patients who underwent pVAD‐assisted PCI and those without pVAD.

Results

Compared with patients not receiving pVAD ( N = 579), those treated with pVAD ( N = 142) more likely had heart failure, lower left ventricular ejection fraction (30.7 ± 13.6 vs. 45.9 ± 15.5, p < 0.01), and higher STS 30‐day predicted mortality (4.2 [2.1−8.0] vs. 3.3 [1.7−6.6], p = 0.01) and SYNTAX scores (36.1 ± 12.2, vs. 31.5 ± 12.1, p < 0.01). While the pVAD group had higher in‐hospital (5.6% vs. 2.2%, p = 0.046), 30‐day (9.0% vs. 4.0%, p = 0.01) and 6‐month (20.4% vs. 11.7%, p < 0.01) mortality compared to patients without pVAD, this difference appeared to be largely driven by significantly higher mortality among the 20 (14%) patients with unplanned pVAD use (30% in‐hospital mortality with unplanned PVAD vs. 1.6% with planned, p < 0.01; 30‐day mortality, 38.1% vs. 4.5%, p < 0.01). The degree of 6‐month health status improvement among survivors was similar between groups.

Conclusion

Surgically ineligible patients with pVAD‐assisted PCI had more complex baseline characteristics compared with those without pVAD. Higher mortality in the pVAD group appeared to be driven by very poor outcomes by patients with unplanned, rescue pVAD.

Subjects

MeSH terms (MEDLINE)

Percutaneous Coronary InterventionHeart-Assist DevicesHumansStroke VolumeProspective StudiesTreatment OutcomeRetrospective StudiesVentricular Function, LeftShock, Cardiogenic

Author keywords

high-risk percutaneous coronary interventionpercutaneous ventricular assist devicequality of lifesurgical ineligible

Authors and institutions

  • Division of Cardiology, University of Missouri, Columbia, Missouri, USA.
  • Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
  • Divison of Cardiology, University of Missouri Kansas City, Kansas City, Missouri, USA.
  • Piedmont Heart Institute, Atlanta, Georgia, USA.
  • Columbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, New York, USA.
  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

ORCID profiles: Taishi Hirai, Ajay J Kirtane, Adam C Salisbury

Funding

  • Boston Scientific Corporation
  • Abiomed

Cite

APA

Hirai, T., Grantham, J. A., Kandzari, D. E., Ballard, W., Brown, W. M., Allen, K. B., Kirtane, A. J., Argenziano, M., Yeh, R. W., Khabbaz, K., Lombardi, W., Lasala, J., Kachroo, P., Karmpaliotis, D., Gosch, K. L., Salisbury, A. C., & OPTIMUM Study Group (2023). Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30834

Vancouver

Hirai T, Grantham JA, Kandzari DE, Ballard W, Brown WM, Allen KB, et al. Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30834

BibTeX
@article{Hirai2023,
  author = {Hirai, Taishi and Grantham, J Aaron and Kandzari, David E and Ballard, William and Brown, W Morris and Allen, Keith B and Kirtane, Ajay J and Argenziano, Michael and Yeh, Robert W and Khabbaz, Kamal and Lombardi, William and Lasala, John and Kachroo, Puja and Karmpaliotis, Dimitri and Gosch, Kensey L and Salisbury, Adam C and OPTIMUM Study Group, OPTIMUM Study Group},
  title = {Percutaneous ventricular assist device for higher‐risk percutaneous coronary intervention in surgically ineligible patients: Indications and outcomes from the OPTIMUM study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2023},
  doi = {10.1002/ccd.30834}
}
Start for free →